The fatty liver in children is a diagnostic and a therapeutic challenge. The most common cause of liver steatosis is the non-alcoholic fatty liver disease (NAFLD), whose importance has increased along with the obesity epidemic. However, ruling out monogenic disorders of metabolism – potentially susceptible of specific treatment – is paramount in young patients. Research in the field has unveiled genetic and epigenetic disease modifiers, and several candidate biomarkers have been selected for non-invasive disease assessment.
We want to offer an updated perspective of the management of the child with fatty liver disease, and interactive discussion about existing controversies and current needs in clinical practice. Future perspectives as well as novelties from basic science will be addressed.